GlassScriptPhysician profile
Shadi Razmdjou
NPI 1154703585
$3,793.41
in general payments reported to CMS, 2019-2025
26 companies · $16.11 in 2025
The $16.11 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.79 · 2021: $1,877 · 2022: $1,298 · 2023: $572 · 2025: $16.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $1,666.67 | 2021 | |
| Abbvie INC. | $574.43 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.10 | 2022-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $185.16 | 2022-2023 | Gattex |
| Medtronic, INC. | $146.89 | 2021 | |
| Qol Medical, LLC | $106.09 | 2021-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $82.81 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $82.75 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $69.63 | 2022-2023 | Ocaliva |
| Daiichi Sankyo INC. | $67.10 | 2021-2022 | |
| Amgen INC. | $59.98 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $56.82 | 2021-2022 | |
| Janssen Biotech, INC. | $55.76 | 2022-2023 | Stelara, Remicade, Simponi |
| Ardelyx, INC. | $49.27 | 2022 | |
| Genzyme Corporation | $43.96 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $42.25 | 2022 | |
| Redhill Biopharma INC. | $40.03 | 2022 | |
| Organon LLC | $36.69 | 2022 | |
| Pfizer INC. | $36.40 | 2023-2025 | |
| Celgene Corporation | $34.68 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $32.39 | 2022-2023 | Linzess |
| Boston Scientific Corporation | $30.79 | 2019 | |
| Pharmacosmos Therapeutics INC. | $21.42 | 2022 | |
| Currax Pharmaceuticals LLC | $15.84 | 2022 | |
| Braintree Laboratories, INC. | $14.86 | 2022 | |
| Merck Sharp & Dohme LLC | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Razmdjou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.